- Home
- EHI vs SLN Comparison
EHI vs SLN Comparison
Compare EHI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHI
- SLN
- Stock Information
- Founded
- EHI 2003
- SLN 1994
- Country
- EHI United States
- SLN United Kingdom
- Employees
- EHI N/A
- SLN N/A
- Industry
- EHI Investment Managers
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- EHI Finance
- SLN Health Care
- Exchange
- EHI Nasdaq
- SLN Nasdaq
- Market Cap
- EHI 194.8M
- SLN 165.3M
- IPO Year
- EHI N/A
- SLN N/A
- Fundamental
- Price
- EHI $6.47
- SLN $5.80
- Analyst Decision
- EHI
- SLN Buy
- Analyst Count
- EHI 0
- SLN 5
- Target Price
- EHI N/A
- SLN $32.60
- AVG Volume (30 Days)
- EHI 44.5K
- SLN 123.0K
- Earning Date
- EHI 01-01-0001
- SLN 08-14-2025
- Dividend Yield
- EHI 11.54%
- SLN N/A
- EPS Growth
- EHI N/A
- SLN N/A
- EPS
- EHI N/A
- SLN N/A
- Revenue
- EHI N/A
- SLN $27,701,000.00
- Revenue This Year
- EHI N/A
- SLN N/A
- Revenue Next Year
- EHI N/A
- SLN N/A
- P/E Ratio
- EHI N/A
- SLN N/A
- Revenue Growth
- EHI N/A
- SLN N/A
- 52 Week Low
- EHI $6.00
- SLN $1.97
- 52 Week High
- EHI $7.75
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- EHI 54.69
- SLN 59.55
- Support Level
- EHI $6.38
- SLN $5.06
- Resistance Level
- EHI $6.50
- SLN $6.25
- Average True Range (ATR)
- EHI 0.04
- SLN 0.49
- MACD
- EHI 0.00
- SLN -0.01
- Stochastic Oscillator
- EHI 76.92
- SLN 64.00
About EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Energy, Healthcare, Industrials, materials, and others.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.